# Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab

> **NCT02453776** · PHASE4 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 80 (actual)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **DRUG:** PRECISION dosing Infliximab

## Key facts

- **NCT ID:** NCT02453776
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453776, "Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02453776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*